BBNX (36) IART (32) SIBN (48) SGP (41) ⌘ Pro Terminal →

OrthoPediatrics Corp. (KIDS) — RQD Stock Rating Cockpit

$31.52 +2.34% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

OrthoPediatrics Corp. (KIDS) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $823.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KIDS)Realized 20D OHLCV Swing Band: ±10.6%

RSI-14 MOMENTUMOVERBOUGHT (>70)

77.830 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.00>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

5 / 99-Pt Accounting

52-WEEK LASER RANGE94% OF RANGE

L: $14$31.52H: $33

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 9 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 23 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on KIDS

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (45)

-7.3% ROIC with 73.1% gross margin and -1.94% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (60)

Altman-Z 3.00 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (42)

14/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like KIDS

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KIDS)

✓Walkthrough of KIDS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

KIDS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +109.30%▲ ASCENDING CHANNEL

2026-10-30O $31.74H $31.93L $30.77C $31.52VOL 569.9K

RES: $33.25SUP: $22.14SMA50: $23.32SMA200: $19.56

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KIDS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KIDS Butterfly Map → + Track KIDS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +15.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KIDS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KIDS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for KIDS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KIDS)

Health Care Rank #446 of 1016 ⚔️ BBNX vs KIDS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KIDS vs. BBNX, IART, SIBN, SGP)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, OrthoPediatrics Corp. (KIDS) ranks #446 by composite RQD confidence (46/100, grade D) and #382 by equity capitalization ($823.0M). Within this direct 5-issuer industry benchmark cohort, KIDS leads on earnings valuation at N/A trailing P/E, while KIDS leads on capital efficiency and profitability with -7.3% ROIC and 73.1% gross margin. SIBN currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with KIDS at 46/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
KIDS ACTIVE OrthoPediatrics Corp.	D	46/100	—	73.1%	-7.3%	+2.34%	$823.0M	Benchmark Subject
BBNX Beta Bionics Inc.	D-	36/100	—	55.4%	-22.1%	-1.51%	$955.8M	/bbnx-vs-kids →
IART Integra LifeSciences Holdings Corporation	E	32/100	—	50.9%	-35.0%	+4.82%	$998.2M	/iart-vs-kids →
SIBN SI-BONE Inc.	D	48/100	—	79.6%	-10.3%	+2.66%	$1.00B	/sibn-vs-kids →
SGP SpyGlass Pharma Inc.	D-	41/100	—	—	-35.0%	-1.06%	$1.09B	/sgp-vs-kids →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001425450

In its most recent audited fiscal period (FY2025, filed 2025-12-31), OrthoPediatrics Corp. (KIDS) reported GAAP revenue of $236.3M (+15.4% vs. FY2024 revenue of $204.7M , and +58.9% cumulative change since FY2023) , GAAP net income of -$39.6M, operating cash flow of -$4.9M, and free cash flow of -$16.0M (+61.4% YoY). On the balance sheet, KIDS closed FY2025 with $508.6M in total assets against $99.8M in total debt (Altman Z-Score: 3.00, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$236.3M	-$39.6M	-$4.9M	-$16.0M	$508.6M	$99.8M
FY2024 (FY)	2024-12-31	$204.7M	-$37.8M	-$27.0M	-$41.3M	$473.2M	$73.0M
FY2023 (FY)	2023-12-31	$148.7M	-$21.0M	-$27.0M	-$27.0M	—	—

3. KIDS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KIDS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, OrthoPediatrics Corp. (NASDAQ: KIDS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $31.52 (+2.34% 1D, market cap $823.0M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, KIDS ranks #446 in composite RQD confidence.

How does KIDS compare to BBNX and IART in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), KIDS carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of 73.1%, and ROIC of -7.3%. By comparison, BBNX (Beta Bionics Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -22.1%, cap $955.8M) and IART (Integra LifeSciences Holdings Corporation) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $998.2M). Among the 5-stock peer group, KIDS leads on earnings multiple (N/A) while KIDS leads on capital efficiency (-7.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KIDS?

Per KIDS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001425450), OrthoPediatrics Corp. generated $236.3M in revenue (+15.4% YoY), -$39.6M in net income, and -$16.0M in free cash flow against $508.6M in total assets and $99.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KIDS trading relative to its 50-day, 200-day, and 52-week technical levels?

KIDS last traded at $31.52 (+2.34% on volume of 835,010 shares), positioning the stock +35.16% above its 50-day simple moving average ($23.32) and +61.15% above its 200-day simple moving average ($19.56). Across its 52-week range of $14.42 to $32.62, KIDS sits at the 94.0% percentile with a 14-day RSI of 77.8 (OVERBOUGHT (>70)) and an implied next-earnings move of ±10.6% ($28.18 to $34.86).

KIDS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell KIDS stock right now?

OrthoPediatrics Corp. (KIDS) currently earns a Roarable Rating of D (Sell — SELL) with 46/100 RQD Confidence. Stretched risk/reward at current multiples (-7% return on capital) under elevated 10-year interest-rate pressure.

What is KIDS's 12-month price target and RQD AI Jury consensus?

KIDS's 12-month base price target is $29.82 (range $23.26 to $35.19), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: KIDS RQD Cockpit KIDS 12M Forecast KIDS Earnings & Move KIDS Dividends & DRIP KIDS Insiders & 13F KIDS Whale Options KIDS Profit Sankey KIDS News & Why